Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials.

ABSTRACT:

Purpose

Breathlessness is a predominant symptom of chronic obstructive pulmonary disease (COPD), making it a valuable outcome in addition to lung function to assess treatment benefit. The phosphodiesterase-4 inhibitor roflumilast has been shown to provide small but significant improvements in dyspnea, as measured by the transition dyspnea index (TDI), in two 1-year studies in patients with severe to very severe COPD.

Patients and methods

To provide a more comprehensive assessment of the impact of roflumilast on dyspnea, post hoc analyses of four 1-year roflumilast studies (M2-111, M2-112, M2-124, and M2-125) in patients with moderate to very severe COPD were conducted.

Results

In this pooled analysis (N=5,595), roflumilast significantly improved TDI focal scores versu

SUBMITTER: Rennard SI 

PROVIDER: S-EPMC4075954 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature